Interestingly, investigators found the therapeutic benefit of anti-IL-6 antibody to be dependent on CD8+ T cells, as CD8-depleted mice did not demonstrate the reduction in tumour size or increase in survival that were observed in control mice and CD4-depleted mice following anti-IL-6 treatment. Here, CD8A is linked to neoplasm.